Department of Neonatology, IPGME&R, Kolkata 700020, India.
Neonatology Division, Department of Pediatrics, Medical College and Hospital, Kolkata 700073, India.
J Trop Pediatr. 2022 Feb 3;68(2). doi: 10.1093/tropej/fmac021.
This study compared the risk of hypoglycemia within 72 h of life in infants with and without exposure to antenatal dexamethasone in the late preterm period (34-366/7 week's gestational age).
This prospective cohort study was conducted in a tertiary care neonatal unit of Eastern India from May 2021 to November 2021. Babies in the exposed group received at least one dose of antenatal dexamethasone in the late preterm period between 7 days before delivery and birth. 'Complete course' of antenatal steroid was defined as four doses of injection dexamethasone at 12 h intervals and <4 doses were considered as 'Partial course'. Primary outcome was incidence of hypoglycemia within 72 h of life, defined as whole blood glucose <45 mg/dl.
Total 298 infants (98 in control, 134 in partial and 66 in complete group) were assessed for final outcome. No significant difference in outcomes were seen in the exposed group compared to unexposed group. However, incidence of hypoglycemia within 72 h (complete vs. partial p= 0.008, complete vs. control p=0.005) and 12 h of life (complete vs. partial p=0.013, complete vs. control p=0.013) was significantly less in complete steroid group. Logistic regression analysis revealed complete course of antenatal corticosteroid significantly decreased the risk of hypoglycemia [adjusted odds ratio, 95% confidence interval (CI) 0.15 (0.03-0.69), p=0.015]. Number needed to be exposed for one additional benefit was 7 (95% CI, 6.35-22.14).
Complete course of dexamethasone administered to mothers at risk of late preterm delivery reduces risk of neonatal hypoglycemia within 72 h of life.
本研究比较了接受和未接受产前地塞米松治疗的晚期早产儿(34-366/7 孕周)在生命后 72 小时内发生低血糖的风险。
本前瞻性队列研究于 2021 年 5 月至 2021 年 11 月在印度东部的一家三级保健新生儿病房进行。暴露组的婴儿在晚期早产期间(分娩前 7 天至出生)至少接受了一次产前地塞米松治疗。“完整疗程”的产前类固醇定义为每 12 小时注射 4 剂地塞米松,<4 剂被认为是“部分疗程”。主要结局是出生后 72 小时内发生低血糖的发生率,定义为全血血糖<45mg/dl。
共有 298 名婴儿(对照组 98 名,部分疗程组 134 名,完整疗程组 66 名)评估了最终结局。与未暴露组相比,暴露组的结局无显著差异。然而,完整疗程组出生后 72 小时(完整疗程 vs. 部分疗程 p=0.008,完整疗程 vs. 对照组 p=0.005)和 12 小时内(完整疗程 vs. 部分疗程 p=0.013,完整疗程 vs. 对照组 p=0.013)发生低血糖的发生率显著降低。逻辑回归分析显示,产前皮质类固醇的完整疗程显著降低了低血糖的风险[调整后的优势比,95%置信区间(CI)0.15(0.03-0.69),p=0.015]。需要暴露的人数以获得额外的益处为 7(95%CI,6.35-22.14)。
在有晚期早产儿分娩风险的母亲中使用地塞米松完整疗程可降低生命后 72 小时内新生儿低血糖的风险。